Other

Forest Laboratories Holdings Limited

Trevena, Inc.

Actavis Group Ptc Ehf

Ironwood Pharmaceuticals, Inc.

Ritesh Sanghvi

Mark G Currie

Angelika Fretzen

Rahul Surana

Andreas Grill

Matthew Ronsheim

Anil Chhettry

Ahmad Hashash

Graham Richard Lawton

Shao Hong Zhou

Yuriy B Kalyan

Yun Mo

Haijian Zhu

Gregory Alcorn

Hiajian (Jim) Zhu

Jiaher Tian

Matthew Miller

Meiki Yu

Mohammad Mafruhul Bari

Joseph Stainkamp

David Farrington

Richard Anthony Flynn

Mahendra Dedihiya

Described herein are micronized powder particles of colistimethate sodium wherein at least 50% by volume of the micronized particles have a diameter of less than 7 micrometers but not less than 3 micrometers and the powder has a total moisture content of from 5 to 10% by weight, for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistimethate sodium is not separated into component form. The micronized powder particles of colistimethate sodium are useful in the treatment of infections caused by gram-negative bacteria, particularly in patients suffering from cystic fibrosis.

Micronized colistimethane sodium pharmaceutical compositions

The present disclosure provides novel crystalline forms of a compound that acts as a &#x3b2;-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a &#x3b2;-arrestin effector and uses thereof.

Crystalline and amorphous forms of a &#x3b2;-arrestin effector

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide compositions

The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.

Crystalline form of linaclotide

Growing community of inventors

Commack, NY, United States of America

Ritesh Sanghvi